Skip to main content

Market Overview

Athenex: Q1 Earnings Insights

Share:

 

Shares of Athenex (NASDAQ:ATNX) moved higher by 2.2% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were down 12.50% over the past year to ($0.27), which beat the estimate of ($0.40).

Revenue of $41,025,000 declined by 12.59% year over year, which beat the estimate of $24,540,000.

Outlook

Athenex hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 06, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/2ip7zqzv

Recent Stock Performance

Company's 52-week high was at $15.24

52-week low: $3.66

Price action over last quarter: down 13.57%

Company Profile

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

 

Related Articles (ATNX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com